Clinical Trial

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Study acronym: IsKia
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirmation of eligibility criteria patients will be randomized to one of the 2 treatment groups in a 1:1 randomization ratio.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-07-20; most recent amendment 2026-07-15.
Status change: Recruiting → Active, Not Recruiting 2022-07-26
Status change: Not Yet Recruiting → Recruiting 2021-01-04
Trial Details
NCT Number NCT04483739
Lead Sponsor European Myeloma Network B.V.
Collaborators: EMN Trial Office S.r.l. Impresa Sociale, Sanofi, Amgen
Conditions Multiple Myeloma
Enrollment 302 participants
Start Date 2020-09-25
Primary Completion 2025-07-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16